e-learning
resources
Monograph
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term oral antibiotic treatment: why, what, when and to whom?
Eva Van Braeckel, Menno M. van der Eerden
Source:
Eur Respir Monogr 2017; 75: 185-205
Journal Issue:
Anti-infectives and the Lung
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Eva Van Braeckel, Menno M. van der Eerden. Long-term oral antibiotic treatment: why, what, when and to whom?. Eur Respir Monogr 2017; 75: 185-205
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
TB vaccination: why, when, how and what?
Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Year: 2014
Positional therapy: who, when and how?
Source: Sleep and Breathing Conference 2021
Year: 2021
Eradication and long-term antibiotic treatment: does it make sense?
Source: International Congress 2014 – PG08 The management of non-CF bronchiectasis: from childhood to adulthood
Year: 2014
TB following targeted and biological therapy: can we predict it?
Source: Virtual Congress 2020 – Tuberculosis and comorbidities
Year: 2020
What do new data concerning triple therapy tell us about the risk of infection?
Source: International Congress 2019 – Exploring the link between inhaled corticosteroids and respiratory infection
Year: 2019
Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think?
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Pharmacotherapy of CSA: who, when and how?
Source: Sleep and Breathing Conference 2021
Year: 2021
Immunotherapy: when, who and which drug?
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018
What’s new in induction therapy
Source: ERS Course 2016
Year: 2016
Cleaning agents and asthma: what does the evidence currently tell us about diagnosis and management of these cases?
Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health?
Year: 2018
Antifungals in pulmonary infections: to whom, when and how?
Source: Eur Respir Monogr 2017; 75: 159-184
Year: 2017
How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017
Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019
What happens when an oral tuberculosis is not treated?
Source: Annual Congress 2007 - Clinical tuberculosis
Year: 2007
Macrolide therapy in asthma: limited treatment, long-term improvement
Source: Eur Respir J 2009; 33: 1239
Year: 2009
Evaluating disease-modifying treatment in CF: are we ready to take the challenge?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept